Factors associated with time- to- treatment of prostate cancer in Florida

Journal of Health Care for the Poor and Underserved

Volumn 24, Issue 4 SUPPL., 2013, Pages 132-146

  Xiao, Hong ^a   Tan, Fei ^b   Goovaerts, Pierre ^c,d   Adunlin, Georges ^a   Ali, Askal ^a   Huang, Youjie ^e   Gwede, Clement K ^f,g  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c BIOMEDWARE INC   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e FLORIDA DEPARTMENT OF HEALTH   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLACK PERSON; CAUCASIAN; COMORBIDITY; EARLY DIAGNOSIS; HOSPITAL; HUMAN; MALE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATHOLOGY; PROSTATE TUMOR; REGISTER; TIME TO TREATMENT; UNITED STATES; VERY ELDERLY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; COMORBIDITY; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLORIDA; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTRIES; TIME-TO-TREATMENT;

EID: 84887806814     PISSN: 10492089     EISSN: 15486869     Source Type: Journal    
DOI: 10.1353/hpu.2014.0005     Document Type: Article

References (38)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society, 2013.
2. Cipolle RJ, Strand LM, Morley PC. Pharmaceutical care practice: the clinician's guide. 2nd ed. New York, NY: McGraw- Hill Companies, Inc; 2004.
3. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: Geographical distribution and secular trends. Mol Nutr Food Res. 2009 Feb; 53(2): 171-184.
4. Hof man RM, Gilliland FD, Eley J W, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001 Mar 7;93(5):388-395.
5. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002 Mar 6; 94(5): 334-357.
6. Hof man RM, Harlan LC, Klabunde CN, et al. Racial differences in initial treatment for clinically localized prostate cancer. J Gen Intern Med. 2003 Oct; 18(10): 845-853.
7. Hall SE, Holman CDAJ, Wisniewski ZS, et al. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival. BJU Int. 2005 Jan;95(1):51-58.
8. Underwood W, Demonner S, Ubel P, et al. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol. 2004 Apr; 171(4): 1504-1507.
9. Schwartz K, Powell IJ, Underwood W, et al. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology. 2009 Dec; 74(6): 1296-1302.
10. Shavers VL, Brown M, Klabunde CN, et al. Race/ethnicity and the intensity of medical monitoring under'watchful waiting'for prostate cancer. Med Care. 2004 Mar; 42(3): 239-250.
11. Spencer BA, Fung CH, Wang M, et al. Geographic variation across veterans af airs medical centers in the treatment of early stage prostate cancer. J Urol. 2004 Dec; 172(6 Pt 1): 2362-2365.
12. Meyer BJF, Talbot A P, Ranalli C. Why older adults make more immediate treatment decisions about cancer than younger adults. Psychol Aging. 2007 Sep; 22(3): 505-524.
13. Gorin SS, Heck JE, Cheng B, et al. Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med. 2006 Nov 13; 166(20): 2244-2252.
14. Smith ER, Adams SA, Das I P, et al. Breast cancer survival among economically dis-advantaged women: The influences of delayed diagnosis and treatment on mortality. Cancer Epidemiology Biomarkers & Prevention. 2008 Oct; 17(10): 2882-2890. Epub 2008 Oct 3.
15. Pocock B, Nash S, Klein L, et al. Disparities in time to definitive surgical treatment between black and white women diagnosed with ductal carcinoma in situ. Am J Surg. 2007 Oct;194(4):521-523.
16. Neal R, Allgar V. Sociodemographic factors and delays in the diagnosis of six cancers: Analysis of data from the National survey of NHS patients: Cancer. Br J Cancer. 2005 Jun 6; 92(11): 1971-1975.
17. Simunovic M, Gagliardi A, McCready D, et al. A snapshot of waiting times for cancer surgery provided by surgeons af liated with regional cancer centres in Ontario. CMAJ. 2001 Aug 21; 165(4): 421-425.
18. Subramonian K, Puranik S, Muf i G. How will the two- weeks- wait rule affect delays in management of urological cancers? J R Soc Med. 2003 Aug; 96(8): 398-399.
19. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate- specific antigen screening: Lessons from US prostate cancer incidence trends. J Natl Cancer Inst. 2002 Jul 3;94(13):981-990.
20. Nam R, Jewett M, Krahn M, et al. Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol. 2003 Jun 10; 10(3): 1891-1898.
21. Andrews SF, Horwitz EM, Feigenberg SJ, et al. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma? Cancer. 2005 Jul 15; 104(2): 299-304.
22. Khan MA, Mangold LA, Epstein JI, et al. Impact of surgical delay on long- term cancer control for clinically localized prostate cancer. J Urol. 2004 Nov; 172(5 Pt 1): 1835-1839.
23. Freedland SJ, Kane CJ, Amling CL, et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr; 175(4): 1298-1302; discussion 1302-3.
24. Nguyen PL, Whittington R, Koo S, et al. The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate carcinoma. Cancer. 2005 May 15; 103(10): 2053-2059.
25. Saad F, Finelli A, Dranitsaris G, et al. Does prolonging the time to prostate cancer surgery impact long- term cancer control: A systematic review of the literature. Can J Urol. 2006 Jun; 13 Suppl 3: 16-24.
26. Florida Cancer Data System (FCDS). FCDS. Miami, FL. 2013.
27. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998; 36(1): 8.
28. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association. 1989 Dec; 84(408): 1065-1073.
29. Johnston GM, MacGarvie VL, Elliott D, et al. Radiotherapy wait times for patients with a diagnosis of invasive cancer, 1992-2000. Clin Invest Med. 2004 Jun; 27(3): 142-156.
30. Siemens DR, Schulze KM, Mackillop WJ, et al. A population- based study of the waiting times for prostatectomy in Ontario. Can J Urol. 2005 Apr; 12(2): 2568-2574.
31. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. Jan 2011; 29(2): 235-241. Epub 2010 Dec 6.
32. Post P, Hansen B, Kil P, et al. The independent prognostic value of comorbidity among men aged< 75 years with localized prostate cancer: a population-based study. BJU Int. 2001 Jun; 87(9): 821-826.
33. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011 Sep; 12(9): 905-912. Epub 2011 May 12.
34. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS. 2011 Mar 13; 25(5): 691-700.
35. Landrine H, Corral I. Separate and unequal: Residential segregation and black health disparities. Ethn Dis. 2009 Spring; 19(2): 179-184.
36. Hayanga AJ, Kaiser HE, Sinha R, et al. Residential segregation and access to surgical care by minority populations in US counties. J Am Coll Surg. 2009 Jun; 208(6): 1017-1022. Epub 2009 Apr 17.
37. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. Am J Epidemiol. 2000 Feb 15; 151(4):409-416.
38. Knight SK, Siston AK, Chmiel JS, et al. Ethnic variation in localized prostate cancer: A pilot study of preferences, optimism, and quality of life among black and white veterans. Clin Prostate Cancer. 2004 Jun; 3(1): 31-37.